Purple Biotech Statistics
Share Statistics
Purple Biotech has 13.61K
shares outstanding. The number of shares has increased by -90.43%
in one year.
| Shares Outstanding | 13.61K |
| Shares Change (YoY) | -90.43% |
| Shares Change (QoQ) | 2.53% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 765 |
| FTD / Avg. Volume | 0.73% |
Short Selling Information
The latest short interest is 65.58K, so 2.48% of the outstanding
shares have been sold short.
| Short Interest | 65.58K |
| Short % of Shares Out | 2.48% |
| Short % of Float | 2.54% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.11 and the forward
PE ratio is -1.43.
Purple Biotech's PEG ratio is
0.
| PE Ratio | -0.11 |
| Forward PE | -1.43 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 0.02 |
| P/FCF Ratio | -0.06 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Purple Biotech.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.23,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.23 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.01 |
| Interest Coverage | -268.41 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-804,444.44 |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -84.44% in the
last 52 weeks. The beta is 0.56, so Purple Biotech's
price volatility has been higher than the market average.
| Beta | 0.56 |
| 52-Week Price Change | -84.44% |
| 50-Day Moving Average | 2.54 |
| 200-Day Moving Average | 4.13 |
| Relative Strength Index (RSI) | 54.3 |
| Average Volume (20 Days) | 104,082 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.01M |
| Net Income | -7.24M |
| EBITDA | -7.05M |
| EBIT | -7.24M |
| Earnings Per Share (EPS) | -42 |
Full Income StatementBalance Sheet
The company has 7.4M in cash and 183K in
debt, giving a net cash position of 7.22M.
| Cash & Cash Equivalents | 7.4M |
| Total Debt | 183K |
| Net Cash | 7.22M |
| Retained Earnings | -144.69M |
| Total Assets | 37.04M |
| Working Capital | 4.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -14.37M
and capital expenditures 0, giving a free cash flow of -14.37M.
| Operating Cash Flow | -14.37M |
| Capital Expenditures | n/a |
| Free Cash Flow | -14.37M |
| FCF Per Share | -0.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
